Metastatic melanoma has a five-year survival of~ 10%, with a paucity of biomarkers
predicting metastasis to specific anatomic sites or targeted therapies for metastases. We …

Purpose MDM2 amplification can promote tumorigenesis directly or indirectly through p53
inhibition. MDM2 has increasing clinical relevance because inhibitors are under evaluation …

The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations
in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in …

Malignant melanoma is one of the least chemosensitive human cancers. The cause of drug
resistance in melanoma remains poorly understood. So far, no cytotoxic regimen has …

Background: Metastatic melanoma (MM) represents a common malignancy with poor
prognosis. Immune checkpoint inhibition (ICI), including PD-1 blockade, has been emerging …

Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-
cycle arrest and apoptosis mediated by p53, a tumor suppressor that is mutated in 40% of …

Immune Checkpoint Therapies (ICT) have revolutionized the treatment of metastatic
melanoma. However, only a subset of patients reaches complete responses. Deficient β2 …

Background: Emerging evidence suggests that p53 participates in the regulation of tumor
immunity. TP53 activation in the myeloid linage suppresses alternative (M2) macrophage …

Previous reports have provided evidence that p53 mutation is a strong negative predictor of
response to MDM2 inhibitors. However, this correlation is not absolute, as many p53 Mutant …

Purpose: Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI)
therapy, but many subsequently progress on these therapies. Second-line targeted therapy …